

## Real Problems. Real Solutions.


Prescription drug spend continues to be a major driver of total plan cost — often fueled by ineffective, “trial-and-error” prescribing. When medications don’t work as intended, the result is a costly cycle that leads to avoidable waste, increased medical utilization, and deteriorating member health.

**RxMapper** is a personalized medication solution, developed in collaboration with **Mayo Clinic**, that replaces clinical guesswork with DNA-guided precision. By getting members on the right medications, RxMapper moves your plan from reactive management to proactive interventions.

**90%** of RxMapper patients receive personalized recommendations that are likely to be safe and effective based on their unique DNA. This improves clinical outcomes while reducing unnecessary pharmacy and medical spend — aligning member health with sustainable cost control for employers and health plans.

## RxMapper ROI Guarantee

RxMapper is designed to be a self-funding benefit, delivering an average annual drug spend savings of **\$8,601** and medical spend savings of **\$12,096**—for a total average annual cost savings of **\$20,697** per patient sequenced. This represents an **8.5x to 13x ROI**. As participation grows, the data-driven impact on your plan’s performance continues to compound.

**The VERIS Money-Back Guarantee**

We stand behind the clinical and financial impact of our program. RxMapper guarantees that the aggregate savings achieved for participating Benecon VERIS clients will exceed the total PMPM fees. If the collective savings do not meet this threshold, RxMapper will refund the difference to the participating VERIS employers.

For additional details, contact RxMapper



[sales@rxmapper.com](mailto:sales@rxmapper.com)



1-800-950-3230



<https://www.rxmapper.com/>

## RxMapper Clinical Examples

**Patient:** 52 year-old male

**Diagnosis:** Rheumatoid Arthritis

**VHS Insight:** Avoided specialty escalation and sustained cost containment.

### Baseline:

- Failed methotrexate therapy
- Escalated to HUMIRA
- \$75,600 annual specialty drug cost

### RxMapper Intervention:

- DNA-guided pharmacist consult
- Identified effective oral alternative
- Leflunomide at \$22/month

### Outcome:

- Improved health and symptom control for the patient
- Avoided specialty escalation
- \$75,300 annual savings for client

**Patient:** 43 year-old female, mother of three children

**Diagnosis:** Breast Cancer

**VHS Insight:** Precision therapy based on DNA analysis, avoided aggressive recurrence of cancer

### Baseline:

- Preparing to begin 5-year Tamoxifen regimen
- Elevated risk of poor long-term response
- Potential for ineffective therapy and avoidable risk

### RxMapper Intervention:

- DNA-guided pharmacist consult
- Identified markers linked to Tamoxifen non-response
- Recommended Anastrozole in combination with Lupron

### Outcome:

- Successful DNA-guided treatment
- Cancer remains in remission 8-years later
- Avoided devastating health and financial costs of recurrence

## Integrate through Benecon



### Plan Integration

If you offer RxMapper as a benefit under your health plan, RxMapper's Summary Plan Description (SPD) will be incorporated by reference and attached to your existing plan's SPD.



### Member Eligibility Coordination

Member eligibility is to be provided by the group/consultant directly to RxMapper.



### Billing/Cost

**\$2.75 PMPM, plus \$250 per Sequence Patient**

The PMPM fee is converted to a PEPM fee and billed through Benecon.

Please note that neither the PEPM fee nor the sequencing fee is covered under stop loss. Benecon's billing is provided solely as a convenience.



Visit our website  
to learn more!



To elect RxMapper, contact your consortium account manager.  
This option can be added during the renewal process or at any time throughout the year.

The Benecon Group, LLC, ConnectCare3, LLC, and the VERIS Benefits Consortium, LLC provide vendor options as potential resources based on internal evaluations. These are not endorsements or guarantees of services or performance. No affiliation exists beyond these recommendations unless stated otherwise. Employer groups, their consultants, and legal counsel are responsible for verifying that any vendor or service does not violate existing contracts (including RX rebates) and for conducting independent due diligence. The above entities are not responsible for determining employer or participant eligibility for any vendor programs or services. All decisions to engage vendors are made solely at the employer group's discretion and risk. The above entities do not provide legal advice and disclaim liability for any outcomes from vendor use. Legal consultation is strongly advised before making plan changes.

For additional details, contact RxMapper



[sales@rxmapper.com](mailto:sales@rxmapper.com)



1-800-950-3230



<https://www.rxmapper.com/>